Use of re-randomized data in meta-analysis

BMC Medical Research Methodology

Volumn 5, Issue , 2005, Pages

  Hozo, Iztok ^a   Djulbegovic, Benjamin ^b   Clark, Otavio ^c   Lyman, Gary H ^d  

^a INDIANA UNIVERSITY NORTHWEST   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c Instituto do Radium de Campinas   (Brazil)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; COLONY STIMULATING FACTOR;

ANALYTICAL ERROR; ARTICLE; FEBRILE NEUTROPENIA; MATHEMATICAL MODEL; META ANALYSIS; PROBABILITY; RANDOMIZATION; RELIABILITY; RISK ASSESSMENT; STATISTICAL ANALYSIS; CHEMICALLY INDUCED; HUMAN; META ANALYSIS (TOPIC); NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK; SEIZURES, FEBRILE; SELECTION BIAS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

COLONY-STIMULATING FACTORS; DATA INTERPRETATION, STATISTICAL; HUMANS; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; NEUTROPENIA; ODDS RATIO; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SEIZURES, FEBRILE; SELECTION BIAS;

EID: 21744438585     PISSN: 14712288     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-5-17     Document Type: Article

References (9)

1. Elting LS PM: Controversies and quandaries: The design of clinical trials in fever and neutropenia. In Textbook of febrile neutropenia Edited by: Rolston KVI, Rubenstein EB. London , Martin Dunitz; 2001:p. 27-44.
2. Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis 1990, 161(3):397-401.
3. Clark OA, Lyman G, Castro AA, Clark LG, Djulbegovic B: Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev 2003:CD003039.
4. Chouaid C, Bassinet L, Fuhrman C, Monnet I, Housset B: Routine use of granulocyte colony-stimulating factor is not costeffective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. J Clin Oncol 1998, 16(8):2700-2707.
5. Mitchell PL, Morland B, Stevens MC, Dick G, Easlea D, Meyer LC, Pinkerton CR: Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 1997, 15(3):1163-1170.
6. Anaissie EJ, Vartivarian S, Bodey GP, Legrand C, Kantarjian H, Abi-Said D, Karl C, Vadhan-Raj S: Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. Am J Med 1996, 100(1):17-23.
7. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Somerfield MR: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000, 18(20):3558-3585.
8. Sutton AJ: Methods for meta-analysis in medical research. In Wiley series in probability and statistics Chichester, West Sussex, England ; New York , John Wiley; 2000:xvii, 317.
9. Paesmans M: Statistical considerations in clinical trials testing empiric antibiotic regimens in patients with febrile neutropenia. Support Care Cancer 1998, 6(5):438-443.